Exagen (XGN) Stock News

Exagen Inc. (Nasdaq: XGN) has announced its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 15-17, 2022. CEO Ron Rocca and CFO Kamal Adawi will engage in a virtual fireside chat on February 16 at 2:00 PM ET, accessible to conference attendees. Additionally, one-on-one meetings with investors can be scheduled through BTIG. Exagen specializes in autoimmune testing solutions, aiming to improve care for chronic autoimmune diseases with its AVISE® brand products.

Exagen Inc. (Nasdaq: XGN) has entered a research collaboration and exclusive licensing agreement with Queen Mary University of London to enhance precision medicine approaches for rheumatoid arthritis (RA). This partnership aims to develop patent-pending assays that utilize RNA expression signatures to improve therapeutic selection for RA patients. With approximately two million individuals affected by RA in the U.S., the collaboration seeks to address significant unmet needs in treatment variability. Exagen will market the resulting diagnostics under the AVISE® RADR brand.

Exagen Inc. (Nasdaq: XGN) will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 22 to December 2, 2021. During this period, presentations will be available for registered attendees. On December 1, Exagen will hold one-on-one meetings, which can be requested exclusively through Piper Sandler. Key executives, including President Ron Rocca and CFO Kamal Adawi, will also host a virtual presentation that can be accessed via Exagen’s website. The company focuses on autoimmune testing solutions aimed at improving patient care.

Exagen Inc. (XGN) reported a 14% increase in quarterly revenue, reaching $12.3 million for Q3 2021. The AVISE® CTD test revenue surged by 34% to $9.9 million, driven by a 21% rise in testing volumes with 31,742 tests delivered. The company achieved a record of 1,969 ordering healthcare providers and maintained a 99% retention rate among adopters. However, operational expenses rose to $18.8 million, leading to a net loss of $7.2 million. Exagen reaffirmed its 2021 revenue guidance of $47-$49 million.

Exagen Inc. (Nasdaq: XGN) will participate in the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health and Services Forum on November 18, 2021. Ron Rocca, President and CEO, and Kamal Adawi, CFO, will hold a virtual fireside chat at 10:30 AM ET. Interested viewers can access the live webcast from Exagen’s website. Exagen is focused on autoimmune testing solutions, aiming to enhance diagnosis and treatment for chronic autoimmune diseases such as rheumatoid arthritis and lupus through innovative testing products.

Exagen Inc. (Nasdaq: XGN), a leader in autoimmune testing, will announce its financial results for Q3 2021 on November 10, 2021, after market close. CEO Ron Rocca, CFO Kamal Adawi, and COO Mark Hazeltine will host a conference call at 4:30 PM ET to discuss the results. The call can be accessed via phone or webcast on the Exagen investor relations website. A replay will be available until November 17, 2021. Exagen focuses on improving patient care through innovative testing solutions for autoimmune diseases like rheumatoid arthritis and lupus.

Exagen Inc. (Nasdaq: XGN) has partnered with Inland Empire Health Plan (IEHP) to provide covered AVISE® CTD and AVISE Lupus services to 1.4 million members. This agreement facilitates in-network access to these diagnostic tests, critical for the timely diagnosis of complex autoimmune diseases, including Systemic Lupus Erythematosus (SLE). The partnership aims to enhance patient outcomes by addressing the challenges in diagnosing and treating SLE, which predominantly affects women of color. Exagen focuses on innovative testing solutions to improve autoimmune disease management.

Exagen Inc. (Nasdaq: XGN) announced a $27.2 million 5-year term loan with Innovatus Capital Partners at an 8.0% interest rate, where 2.0% is paid in-kind. This amendment strengthens their relationship, aiming to enhance patient care for autoimmune diseases through innovative testing solutions. The updated terms were disclosed in a Current Report filed on October 25, 2021. The loan is expected to support Exagen's mission of improving patient outcomes and reducing healthcare costs amidst ongoing challenges within the healthcare landscape.

Exagen Inc. (Nasdaq: XGN) will present new research at the virtual ACR Convergence 2021 from November 6-9, 2021. This research focuses on the role of cell-bound complement activation products (CB-CAPs) in diagnosing and treating systemic lupus erythematosus (SLE). Chief Scientific Officer Anja Kammesheidt expressed pride in collaborating with key researchers. Notable presentations include studies examining the clinical utility of multianalyte assays and CB-CAPs in SLE evaluation. Exagen aims to enhance patient care through advanced diagnostic solutions.